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cians’ cost estimates for commonly prescribed drugs. In fact,
physicians’ with inaccurate cost estimates were more likely to be
comfortable with both GSPs and RDPs. Physicians have explicit
opinions regarding the clinical and economic ramiﬁcations of
GSPs and RDPs, and these opinions should be considered in
planning and communicating drug policies.
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OBJECTIVE: To assess the cost and outcomes of a disease man-
agement program (DMP) for the bleeding disorder population
insured by a state insurance plan. METHODS: All bleeding dis-
order patients covered by the plan were enrolled into a DMP
administered by the Indiana Hemophilia & Thrombosis Center
(IHTC). A pre/post intervention study design was used, with a
prior year serving as the baseline period and 1-year post enroll-
ment as the study period. Claims data were used to assess hos-
pitalizations, ER visits, total medical costs and factor costs.
Medical records were used to assess disease severity and other
co-morbidities. T-tests and a regression analysis were used to
assess the impact of the DMP. RESULTS: Thirty continuously
enrolled patients had complete data. Due to the small sample size
and large variability in costs found in this population, none of
the analyses reached statistical signiﬁcance. Approximately 90%
of the population was male, 87% with hemophilia A. The
average cost of care in the baseline year and follow-up year were
$110,637 and $111,329 respectively (p = 0.99). Although factor
use increased by 29,625 units (p = 0.46), and accounted for
90.4% and 96.9% of costs, baseline versus ﬁrst year respectively,
the mean number of inpatient hospital days and ER visits
decreased from 1.36 and 1.6 to 0.43 (p = 0.12), and 0.43 (p =
0.23) respectively. The average total cost for patients who
switched to the DMP during the study period decreased from
$136,725 to $97,557 (p = 0.40) from baseline. CONCLUSION:
Although the DMP did not appear to statistically decrease total
costs, costs were contained even as factor utilization increased.
Additionally, there was a trend toward lower inpatient hospital
days and ER visits. Further enrollment may increase statistical
power and a longer study period will be used to completely assess
the impact of the DMP.
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OBJECTIVE: The Medicare Modernization Act of 2003 requires
drug plan sponsors to provide medication therapy management
(MTM) programs to beneﬁciaries with 1) annual drug expendi-
tures above $4000; 2) multiple comorbidities; and 3) multiple
prescription drugs. The purpose of this study was to obtain
nationally representative estimates of the proportion of seniors
who met the expenditure criteria and identify risk factors for
high annual drug expenditures. METHODS: Prescribed medi-
cines and demographic data came from the 2002 and 2003
Medical Expenditure Panel Survey (MEPS) for respondents ≥65
years of age. Survey-weighted logistic regression identiﬁed risk
factors for high drug expenditures. Candidate variables included
age, gender, race, income, education, marital status, functional
limitations, health status, presence of chronic conditions, body
mass index (BMI), and medical and prescription drug insurance.
Standard errors (SEs) were adjusted for complex survey design
and expenditures were adjusted to 2003 U.S. dollars. Annual
expenses of $3810 in 2003 were deemed equivalent to $4000 in
2005. RESULTS: An estimated 9.2% (SE ± 0.4%) of 36 million
seniors over 2002 and 2003 incurred more than $3810 annual
drug expenditures, accounting for 35% of $55.3 billion in drug
expenditures among all seniors. Respondents with high drug
expenditures reported 10.8 (±0.2) unique medications with
77.9% (±1.9%) reporting ≥8 medications; all had ≥3 medica-
tions. These respondents also had 5.2 (±0.1) chronic conditions;
60.5% (±2.3%) had ≥4 conditions. Diabetes, hyperlipidemia,
depression, and cardiac disease signiﬁcantly increased the risk of
high drug expenditures. Other signiﬁcant risk factors included
receiving help with activities of daily living (ADLs), housework
limitations, high BMI, fair/poor health, and total number of
chronic diseases. CONCLUSION: Respondents with drug
expenditures exceeding the MTM threshold obtain signiﬁcantly
more drugs and have a higher disease burden than those with
lower drug expenditures. Characteristics other than the number
and type of medications can be used to identify candidates for
MTM programs.
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OBJECTIVES: This study examined the prevalence and patterns
of inappropriate medication use among older Medicare managed
care beneﬁciaries enrolled in a Southern California Social Health
Maintenance Organization. METHODS: The administrative
datasets used for the analysis contained demographics, enroll-
ment information, pharmacy claims, inpatient and outpatient
utilization for approximately 75,000 older Medicare beneﬁcia-
ries. The analytical sample included 47,978 members with con-
tinuous enrollment from July 1st 2004 to June 30th 2005. This
study was based on the inappropriate medication list developed
by Zhan (2001). The list was limited to medications that should
always be avoided or considered rarely appropriate regardless of
dose or diagnosis. Patients with at least one prescription claim
for an inappropriate medication were compared to patients
without. Different patterns of inappropriate medication use were
identiﬁed. Univariate and multivariate analyses were performed
to examine characteristics associated with these patterns.
RESULTS: 17.3% (8313/47,978) of the members ﬁlled at least
one claim for a potentially inappropriate medication. 51.2%
(4260/8313) of them ﬁlled multiple prescriptions for potentially
inappropriate medications. The average number of prescribing
providers was higher for members with inappropriate medica-
tions than for those without inappropriate medication claims
(3.84 vs. 2.69, p < 0.0001). Members with inappropriate med-
ication claims ﬁlled an average of 45 medications per year (vs.
32 for other members, p < 0.0001). Logistic regression showed
that inappropriate medication use was associated with younger
age (Odds ratio conﬁdence interval: 0.978–0.985), female gender
(CI:0.612–0.683), number of prescribing providers (CI:1.289–
1.320), and use of home and community-based services —HCBS-
(CI:1.281–1.434). Members who were younger (p = 0.0018),
female (p = 0.0030), dually eligible for Medicare and Medicaid
(p < 0.0001) and using HCBS (p < 0.0001) were more likely to
use multiple inappropriate medications. CONCLUSIONS:
The rate of inappropriate medication use was similar to rates
found in the literature but revealed the importance to develop
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targeted interventions to improve prescribing practices and
patient safety.
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OBJECTIVES: High prices and poor availability of medicines are
major barriers to better health in poor countries. In India, more
than 80% of health care expenditure is “out-of-pocket”. The
study was undertaken to assess medicines prices and the avail-
ability of essential medicines in Rajasthan State, India.
METHODS: Price and availability data for 36 medicines were
measured using a methodology developed by WHO and Health
Action International (HAI). For each medicine, data was col-
lected for the Innovator Brand (IB), Most Sold Generic (MSG),
and Lowest Priced Generic (LPG). In each of four randomly
selected regions, ﬁve public facilities, ﬁve private retail and ﬁve
co-operative pharmacies were surveyed. Prices were compared to
an international reference benchmark (expressed as Median Price
Ratios-MPR). RESULTS: In the public sector, generic medicines
were purchased and provided free of charge to various categories
of people. Procurement prices were reasonable (median MPR
0.96) but the median availability was only 40%. In the private
sector, the median MPR for IB, MSG and LPG was 2.81, 2.72
and 1.83 respectively. The median availability was 0% for IBs,
82.5% for MSGs and 95% for LPGs. Prices in the co-operative
sector were similar to the private pharmacies, but the availabil-
ity was lower. In the private sector, the MPR for three medicines
(LPG) were 8 to 26 times higher than the government procure-
ment prices, indicating very high margins for wholesalers and
retailers. CONCLUSIONS: As the availability of medicines in
the public sector is low, people have to purchase medicines in
the private sector, many of which are high in price. This base-
line survey shows that the Indian government needs to imple-
ment policies to increase the availability of medicines in the
public sector and reduce prices in the private sector.
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OBJECTIVE: Hispanic consumers who do not speak English
may have difﬁculty in interpreting information provided on
Over-the-Counter (OTC) medication labels. This study devel-
oped bilingual Product Information Labels (PILs) for OTCs and
compared them to existing OTC labels. METHODS: The study
had a randomized-within subjects design. Three hundred and
thirty-six consumers, from pharmacy stores in Houston, TX,
participated in the study. Participants were selected randomly
and they viewed, in a random order, each label format for aceta-
minophen, ibuprofen and aspirin. Each label was followed by a
questionnaire for participants. Consumers were divided into
three language categories, namely, only English-speaking, only
Spanish-speaking and bilinguals. Variables measured on the
questionnaire were ease of use, product knowledge, attitude
towards product label, product evaluation and purchase inten-
tion. Data were coded and analyzed using the SAS statistical
package (Version 9.0). Descriptive and comparative statistics
were computed for each variable as well as for all label formats.
RESULTS: Means obtained for PILs were signiﬁcantly different
from those obtained for old and new formats (p < 0.05) for all
consumer categories. A majority of participants were very certain
that they understood the information on PILs (68.15%) and
were very satisﬁed (74.11%) that they understood this informa-
tion shown on the package label. Moreover, about 85% of 
participants who used the Spanish language information on 
PILs found it very useful. CONCLUSIONS: Bilingual PILs, 
as compared existing label formats, are an effective means of 
providing information to all Hispanic consumers. These results
may help the FDA in developing policies to enhance the safety
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